The role of S-nitrosoglutathione reductase (GSNOR) in T cell-mediated immunopathology of experimental autoimmune encephalomyelitis (EAE)

•EAE elevates GSNOR expression/activity in the spinal cord.•GSNOR-deficient mice had milder EAE disease than wild-type mice.•N91115 (GSNOR inhibitor) treated mice had milder EAE disease than untreated mice.•GSNOR inhibition or knockout suppresses Th1/Th17 but boosts Treg cells in EAE. Previously, we...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuroscience 2025-01, Vol.564, p.1-12
Hauptverfasser: Singh, Inderjit, Kim, Judong, Touhidul Islam, S.M., Fei, Qiao, Singh, Avtar K, Won, Jeseong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 12
container_issue
container_start_page 1
container_title Neuroscience
container_volume 564
creator Singh, Inderjit
Kim, Judong
Touhidul Islam, S.M.
Fei, Qiao
Singh, Avtar K
Won, Jeseong
description •EAE elevates GSNOR expression/activity in the spinal cord.•GSNOR-deficient mice had milder EAE disease than wild-type mice.•N91115 (GSNOR inhibitor) treated mice had milder EAE disease than untreated mice.•GSNOR inhibition or knockout suppresses Th1/Th17 but boosts Treg cells in EAE. Previously, we reported that both S-nitrosoglutathione (GSNO), a carrier of cellular nitric oxide, and N6022, an injectable form of GSNO reductase (GSNOR) inhibitor that increases endogenous GSNO levels, alleviate experimental autoimmune encephalomyelitis (EAE) in mice by suppressing Th1 and Th17 immune responses. Building on these findings, we explored the role of GSNOR in EAE pathogenesis and evaluated the efficacy of an orally active GSNOR inhibitor (N91115) in treating the EAE disease. EAE mice exhibited heightened expression/activity of GSNOR in the spinal cord, and the knockout of the GSNOR gene resulted in much milder clinical manifestations of EAE, with lower degrees of demyelination and axonal loss, reduced microglial and astrocyte activations, as well as suppressed Th1 and Th17 cell responses, alongside bolstered Treg immune responses. Next, we evaluated the efficacy of N91115 against EAE immunopathology. Consistent with our findings in GSNOR deficient EAE mice, daily N91115 administration reduced clinical EAE severity, with less spinal cord demyelination and axonal loss compared to untreated EAE mice. Furthermore, N91115 treated EAE mice showed diminished Th1 and Th17 immune responses and enhanced Treg responses. This observation underscores the potential of increased GSNOR expression and activity as a risk factor exacerbating EAE immunopathology, while simultaneously highlighting its potential as a target for modifying the disease. Furthermore, the balanced immune regulation provided by orally active N91115 (IL-6/IL-17a vs. IL-10) presents a promising alternative to immunosuppressive drugs, reducing the risk of opportunistic infections.
doi_str_mv 10.1016/j.neuroscience.2024.11.025
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3128761587</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0306452224006079</els_id><sourcerecordid>3128761587</sourcerecordid><originalsourceid>FETCH-LOGICAL-c253t-9d16251621eff8fe64f95bc991b3c2f1387da4f1785c4484711a6a15f6d191ca3</originalsourceid><addsrcrecordid>eNqNUU2P0zAUtBCILYW_gCxO3UNCnj_ywW21dBekFSux5Wy5zvPWVRKX2EH0H_Cz16EFccSS5YNn5r2ZIeQdFDkUUL7f5wNOow_G4WAwZwUTOUBeMPmMLKCueFZJIZ6TRcGLMhOSsQvyKoR9kY4U_CW54I3kDJpqQX5tdkhH3yH1lj5kg4tJ2D92U9Rx5_yQPrGdTNQB6er24cv910vqBrqhBrsu67F1OmJLXd9Pgz8kju_843EWw58HHF2PQ9Qd1VP0vzFI550PO935_oidiy7Q1fpqffmavLC6C_jm_C7Jt5v15vpTdnd_-_n66i4zTPKYNS2UTKYLaG1tsRS2kVvTNLDlhlngddVqYaGqpRGiFhWALjVIW7bQgNF8SVYn3cPov08YoupdmM3oAf0UFAdWVyXIFOOSfDhBTcokjGjVIRnS41FBoeYm1F7924Sam1AAKjWRyG_Pc6Ztiukv9U_0CfDxBMDk9ofDUZ1lWjeiiar17n_mPAEGGaLx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3128761587</pqid></control><display><type>article</type><title>The role of S-nitrosoglutathione reductase (GSNOR) in T cell-mediated immunopathology of experimental autoimmune encephalomyelitis (EAE)</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Singh, Inderjit ; Kim, Judong ; Touhidul Islam, S.M. ; Fei, Qiao ; Singh, Avtar K ; Won, Jeseong</creator><creatorcontrib>Singh, Inderjit ; Kim, Judong ; Touhidul Islam, S.M. ; Fei, Qiao ; Singh, Avtar K ; Won, Jeseong</creatorcontrib><description>•EAE elevates GSNOR expression/activity in the spinal cord.•GSNOR-deficient mice had milder EAE disease than wild-type mice.•N91115 (GSNOR inhibitor) treated mice had milder EAE disease than untreated mice.•GSNOR inhibition or knockout suppresses Th1/Th17 but boosts Treg cells in EAE. Previously, we reported that both S-nitrosoglutathione (GSNO), a carrier of cellular nitric oxide, and N6022, an injectable form of GSNO reductase (GSNOR) inhibitor that increases endogenous GSNO levels, alleviate experimental autoimmune encephalomyelitis (EAE) in mice by suppressing Th1 and Th17 immune responses. Building on these findings, we explored the role of GSNOR in EAE pathogenesis and evaluated the efficacy of an orally active GSNOR inhibitor (N91115) in treating the EAE disease. EAE mice exhibited heightened expression/activity of GSNOR in the spinal cord, and the knockout of the GSNOR gene resulted in much milder clinical manifestations of EAE, with lower degrees of demyelination and axonal loss, reduced microglial and astrocyte activations, as well as suppressed Th1 and Th17 cell responses, alongside bolstered Treg immune responses. Next, we evaluated the efficacy of N91115 against EAE immunopathology. Consistent with our findings in GSNOR deficient EAE mice, daily N91115 administration reduced clinical EAE severity, with less spinal cord demyelination and axonal loss compared to untreated EAE mice. Furthermore, N91115 treated EAE mice showed diminished Th1 and Th17 immune responses and enhanced Treg responses. This observation underscores the potential of increased GSNOR expression and activity as a risk factor exacerbating EAE immunopathology, while simultaneously highlighting its potential as a target for modifying the disease. Furthermore, the balanced immune regulation provided by orally active N91115 (IL-6/IL-17a vs. IL-10) presents a promising alternative to immunosuppressive drugs, reducing the risk of opportunistic infections.</description><identifier>ISSN: 0306-4522</identifier><identifier>ISSN: 1873-7544</identifier><identifier>EISSN: 1873-7544</identifier><identifier>DOI: 10.1016/j.neuroscience.2024.11.025</identifier><identifier>PMID: 39532197</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Alcohol Dehydrogenase ; Aldehyde Oxidoreductases - antagonists &amp; inhibitors ; Aldehyde Oxidoreductases - metabolism ; Animals ; Encephalomyelitis, Autoimmune, Experimental - drug therapy ; Encephalomyelitis, Autoimmune, Experimental - immunology ; Encephalomyelitis, Autoimmune, Experimental - metabolism ; Encephalomyelitis, Autoimmune, Experimental - pathology ; experimental autoimmune encephalomyelitis (EAE) ; Female ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Microglia - drug effects ; Microglia - metabolism ; Microglia - pathology ; Multiple sclerosis ; S-nitrosoglutathione (GSNO) ; S-nitrosoglutathione reductase (GSNOR) ; Spinal Cord - drug effects ; Spinal Cord - immunology ; Spinal Cord - metabolism ; Spinal Cord - pathology ; T cells ; Th1 Cells - drug effects ; Th1 Cells - immunology ; Th17 Cells - drug effects ; Th17 Cells - immunology</subject><ispartof>Neuroscience, 2025-01, Vol.564, p.1-12</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c253t-9d16251621eff8fe64f95bc991b3c2f1387da4f1785c4484711a6a15f6d191ca3</cites><orcidid>0000-0003-2408-0386</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.neuroscience.2024.11.025$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39532197$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singh, Inderjit</creatorcontrib><creatorcontrib>Kim, Judong</creatorcontrib><creatorcontrib>Touhidul Islam, S.M.</creatorcontrib><creatorcontrib>Fei, Qiao</creatorcontrib><creatorcontrib>Singh, Avtar K</creatorcontrib><creatorcontrib>Won, Jeseong</creatorcontrib><title>The role of S-nitrosoglutathione reductase (GSNOR) in T cell-mediated immunopathology of experimental autoimmune encephalomyelitis (EAE)</title><title>Neuroscience</title><addtitle>Neuroscience</addtitle><description>•EAE elevates GSNOR expression/activity in the spinal cord.•GSNOR-deficient mice had milder EAE disease than wild-type mice.•N91115 (GSNOR inhibitor) treated mice had milder EAE disease than untreated mice.•GSNOR inhibition or knockout suppresses Th1/Th17 but boosts Treg cells in EAE. Previously, we reported that both S-nitrosoglutathione (GSNO), a carrier of cellular nitric oxide, and N6022, an injectable form of GSNO reductase (GSNOR) inhibitor that increases endogenous GSNO levels, alleviate experimental autoimmune encephalomyelitis (EAE) in mice by suppressing Th1 and Th17 immune responses. Building on these findings, we explored the role of GSNOR in EAE pathogenesis and evaluated the efficacy of an orally active GSNOR inhibitor (N91115) in treating the EAE disease. EAE mice exhibited heightened expression/activity of GSNOR in the spinal cord, and the knockout of the GSNOR gene resulted in much milder clinical manifestations of EAE, with lower degrees of demyelination and axonal loss, reduced microglial and astrocyte activations, as well as suppressed Th1 and Th17 cell responses, alongside bolstered Treg immune responses. Next, we evaluated the efficacy of N91115 against EAE immunopathology. Consistent with our findings in GSNOR deficient EAE mice, daily N91115 administration reduced clinical EAE severity, with less spinal cord demyelination and axonal loss compared to untreated EAE mice. Furthermore, N91115 treated EAE mice showed diminished Th1 and Th17 immune responses and enhanced Treg responses. This observation underscores the potential of increased GSNOR expression and activity as a risk factor exacerbating EAE immunopathology, while simultaneously highlighting its potential as a target for modifying the disease. Furthermore, the balanced immune regulation provided by orally active N91115 (IL-6/IL-17a vs. IL-10) presents a promising alternative to immunosuppressive drugs, reducing the risk of opportunistic infections.</description><subject>Alcohol Dehydrogenase</subject><subject>Aldehyde Oxidoreductases - antagonists &amp; inhibitors</subject><subject>Aldehyde Oxidoreductases - metabolism</subject><subject>Animals</subject><subject>Encephalomyelitis, Autoimmune, Experimental - drug therapy</subject><subject>Encephalomyelitis, Autoimmune, Experimental - immunology</subject><subject>Encephalomyelitis, Autoimmune, Experimental - metabolism</subject><subject>Encephalomyelitis, Autoimmune, Experimental - pathology</subject><subject>experimental autoimmune encephalomyelitis (EAE)</subject><subject>Female</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Knockout</subject><subject>Microglia - drug effects</subject><subject>Microglia - metabolism</subject><subject>Microglia - pathology</subject><subject>Multiple sclerosis</subject><subject>S-nitrosoglutathione (GSNO)</subject><subject>S-nitrosoglutathione reductase (GSNOR)</subject><subject>Spinal Cord - drug effects</subject><subject>Spinal Cord - immunology</subject><subject>Spinal Cord - metabolism</subject><subject>Spinal Cord - pathology</subject><subject>T cells</subject><subject>Th1 Cells - drug effects</subject><subject>Th1 Cells - immunology</subject><subject>Th17 Cells - drug effects</subject><subject>Th17 Cells - immunology</subject><issn>0306-4522</issn><issn>1873-7544</issn><issn>1873-7544</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUU2P0zAUtBCILYW_gCxO3UNCnj_ywW21dBekFSux5Wy5zvPWVRKX2EH0H_Cz16EFccSS5YNn5r2ZIeQdFDkUUL7f5wNOow_G4WAwZwUTOUBeMPmMLKCueFZJIZ6TRcGLMhOSsQvyKoR9kY4U_CW54I3kDJpqQX5tdkhH3yH1lj5kg4tJ2D92U9Rx5_yQPrGdTNQB6er24cv910vqBrqhBrsu67F1OmJLXd9Pgz8kju_843EWw58HHF2PQ9Qd1VP0vzFI550PO935_oidiy7Q1fpqffmavLC6C_jm_C7Jt5v15vpTdnd_-_n66i4zTPKYNS2UTKYLaG1tsRS2kVvTNLDlhlngddVqYaGqpRGiFhWALjVIW7bQgNF8SVYn3cPov08YoupdmM3oAf0UFAdWVyXIFOOSfDhBTcokjGjVIRnS41FBoeYm1F7924Sam1AAKjWRyG_Pc6Ztiukv9U_0CfDxBMDk9ofDUZ1lWjeiiar17n_mPAEGGaLx</recordid><startdate>20250109</startdate><enddate>20250109</enddate><creator>Singh, Inderjit</creator><creator>Kim, Judong</creator><creator>Touhidul Islam, S.M.</creator><creator>Fei, Qiao</creator><creator>Singh, Avtar K</creator><creator>Won, Jeseong</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2408-0386</orcidid></search><sort><creationdate>20250109</creationdate><title>The role of S-nitrosoglutathione reductase (GSNOR) in T cell-mediated immunopathology of experimental autoimmune encephalomyelitis (EAE)</title><author>Singh, Inderjit ; Kim, Judong ; Touhidul Islam, S.M. ; Fei, Qiao ; Singh, Avtar K ; Won, Jeseong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c253t-9d16251621eff8fe64f95bc991b3c2f1387da4f1785c4484711a6a15f6d191ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Alcohol Dehydrogenase</topic><topic>Aldehyde Oxidoreductases - antagonists &amp; inhibitors</topic><topic>Aldehyde Oxidoreductases - metabolism</topic><topic>Animals</topic><topic>Encephalomyelitis, Autoimmune, Experimental - drug therapy</topic><topic>Encephalomyelitis, Autoimmune, Experimental - immunology</topic><topic>Encephalomyelitis, Autoimmune, Experimental - metabolism</topic><topic>Encephalomyelitis, Autoimmune, Experimental - pathology</topic><topic>experimental autoimmune encephalomyelitis (EAE)</topic><topic>Female</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Knockout</topic><topic>Microglia - drug effects</topic><topic>Microglia - metabolism</topic><topic>Microglia - pathology</topic><topic>Multiple sclerosis</topic><topic>S-nitrosoglutathione (GSNO)</topic><topic>S-nitrosoglutathione reductase (GSNOR)</topic><topic>Spinal Cord - drug effects</topic><topic>Spinal Cord - immunology</topic><topic>Spinal Cord - metabolism</topic><topic>Spinal Cord - pathology</topic><topic>T cells</topic><topic>Th1 Cells - drug effects</topic><topic>Th1 Cells - immunology</topic><topic>Th17 Cells - drug effects</topic><topic>Th17 Cells - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singh, Inderjit</creatorcontrib><creatorcontrib>Kim, Judong</creatorcontrib><creatorcontrib>Touhidul Islam, S.M.</creatorcontrib><creatorcontrib>Fei, Qiao</creatorcontrib><creatorcontrib>Singh, Avtar K</creatorcontrib><creatorcontrib>Won, Jeseong</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singh, Inderjit</au><au>Kim, Judong</au><au>Touhidul Islam, S.M.</au><au>Fei, Qiao</au><au>Singh, Avtar K</au><au>Won, Jeseong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of S-nitrosoglutathione reductase (GSNOR) in T cell-mediated immunopathology of experimental autoimmune encephalomyelitis (EAE)</atitle><jtitle>Neuroscience</jtitle><addtitle>Neuroscience</addtitle><date>2025-01-09</date><risdate>2025</risdate><volume>564</volume><spage>1</spage><epage>12</epage><pages>1-12</pages><issn>0306-4522</issn><issn>1873-7544</issn><eissn>1873-7544</eissn><abstract>•EAE elevates GSNOR expression/activity in the spinal cord.•GSNOR-deficient mice had milder EAE disease than wild-type mice.•N91115 (GSNOR inhibitor) treated mice had milder EAE disease than untreated mice.•GSNOR inhibition or knockout suppresses Th1/Th17 but boosts Treg cells in EAE. Previously, we reported that both S-nitrosoglutathione (GSNO), a carrier of cellular nitric oxide, and N6022, an injectable form of GSNO reductase (GSNOR) inhibitor that increases endogenous GSNO levels, alleviate experimental autoimmune encephalomyelitis (EAE) in mice by suppressing Th1 and Th17 immune responses. Building on these findings, we explored the role of GSNOR in EAE pathogenesis and evaluated the efficacy of an orally active GSNOR inhibitor (N91115) in treating the EAE disease. EAE mice exhibited heightened expression/activity of GSNOR in the spinal cord, and the knockout of the GSNOR gene resulted in much milder clinical manifestations of EAE, with lower degrees of demyelination and axonal loss, reduced microglial and astrocyte activations, as well as suppressed Th1 and Th17 cell responses, alongside bolstered Treg immune responses. Next, we evaluated the efficacy of N91115 against EAE immunopathology. Consistent with our findings in GSNOR deficient EAE mice, daily N91115 administration reduced clinical EAE severity, with less spinal cord demyelination and axonal loss compared to untreated EAE mice. Furthermore, N91115 treated EAE mice showed diminished Th1 and Th17 immune responses and enhanced Treg responses. This observation underscores the potential of increased GSNOR expression and activity as a risk factor exacerbating EAE immunopathology, while simultaneously highlighting its potential as a target for modifying the disease. Furthermore, the balanced immune regulation provided by orally active N91115 (IL-6/IL-17a vs. IL-10) presents a promising alternative to immunosuppressive drugs, reducing the risk of opportunistic infections.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39532197</pmid><doi>10.1016/j.neuroscience.2024.11.025</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-2408-0386</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0306-4522
ispartof Neuroscience, 2025-01, Vol.564, p.1-12
issn 0306-4522
1873-7544
1873-7544
language eng
recordid cdi_proquest_miscellaneous_3128761587
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Alcohol Dehydrogenase
Aldehyde Oxidoreductases - antagonists & inhibitors
Aldehyde Oxidoreductases - metabolism
Animals
Encephalomyelitis, Autoimmune, Experimental - drug therapy
Encephalomyelitis, Autoimmune, Experimental - immunology
Encephalomyelitis, Autoimmune, Experimental - metabolism
Encephalomyelitis, Autoimmune, Experimental - pathology
experimental autoimmune encephalomyelitis (EAE)
Female
Mice
Mice, Inbred C57BL
Mice, Knockout
Microglia - drug effects
Microglia - metabolism
Microglia - pathology
Multiple sclerosis
S-nitrosoglutathione (GSNO)
S-nitrosoglutathione reductase (GSNOR)
Spinal Cord - drug effects
Spinal Cord - immunology
Spinal Cord - metabolism
Spinal Cord - pathology
T cells
Th1 Cells - drug effects
Th1 Cells - immunology
Th17 Cells - drug effects
Th17 Cells - immunology
title The role of S-nitrosoglutathione reductase (GSNOR) in T cell-mediated immunopathology of experimental autoimmune encephalomyelitis (EAE)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T23%3A05%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20S-nitrosoglutathione%20reductase%20(GSNOR)%20in%20T%20cell-mediated%20immunopathology%20of%20experimental%20autoimmune%20encephalomyelitis%20(EAE)&rft.jtitle=Neuroscience&rft.au=Singh,%20Inderjit&rft.date=2025-01-09&rft.volume=564&rft.spage=1&rft.epage=12&rft.pages=1-12&rft.issn=0306-4522&rft.eissn=1873-7544&rft_id=info:doi/10.1016/j.neuroscience.2024.11.025&rft_dat=%3Cproquest_cross%3E3128761587%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3128761587&rft_id=info:pmid/39532197&rft_els_id=S0306452224006079&rfr_iscdi=true